FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
Related Articles
Pathways & Perspectives with Alice Mims, MD – SOHO Insider
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s role in…
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig…
I Struggled With Obesity My Whole Life—Until I Went Plant-Based
After decades of obesity and chronic illness, Deena lost 270 pounds and reclaimed her health after going plant-based.
What Is Lipoprotein(a)? Understanding Its Role in Vascular Health and Cholesterol
Knowing your levels and maintaining a healthy heart could keep things in check
Information for Authors: JAAD Case Reports
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. The Journal of…
Real-World Data Analysis Suggests Crizanlizumab Reduces SCD Acute Care Need | Docwire News
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
FDA, Biotech Company Hash Out Criteria for Primary Vitreoretinal Lymphoma Agent’s NDA Resubmission | Blood Cancers Today
The agent, investigational drug candidate ADX-2191, is a novel intravitreal injection formulation of methotrexate.
Premenstrual disorders may indicate a higher risk for heart disease, study finds
Researchers found an 11% higher risk for cardiovascular disease in women diagnosed with severe symptoms, not just mild or moderate cramps.
Open Comment of Guidelines – ASCO
Open comment allows key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication. It…
Transcatheter Tricuspid Valve Replacement After Failed Transcatheter Annuloplasty and Edge-to-Edge Repair:
AbstractBackgroundThe EVOQUE transcatheter tricuspid heart valve (Edwards Lifesciences) is approved for high-risk patients with severe tricuspid regurgitation (TR). This report describes the first …
